北欧共识文件关于Evolut FX+跨导管大动脉植入:优化索引植入和长期结果
Arif A Khokhar1, Mikko Savontaus2, Ahmed Al-Ani3
1Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Frontiers in cardiovascular medicine
|November 26, 2025
概括
使用Evolut FX(+) 门进行过导管大动脉置换 (TAVI) 为严重的大动脉狭窄提供了安全有效的治疗方法. 代设计改进旨在优化门植入以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 医疗器械技术 医疗器械技术
背景情况:
- 严重的症状性大动脉狭窄症 (AS) 需要干预.
- 过导管大动脉置换 (TAVI) 是对AS的经过验证的治疗方法.
- 核心/Evolut平台证明了安全性,有效性和耐用性.
研究的目的:
- 描述最新一代Evolut FX(+) 跨导管大动脉 (TAV) 的代设计变化.
- 解释这些变化如何促进优化的索引植入.
- 支持TAVI扩展到年轻的患者,寿命更长.
主要方法:
- 关于Evolut FX(+) TAV平台的技术叙述审查.
- 专注于影响植入的设计代.
- 讨论如何实现最佳的索引植入.
主要成果:
- 进化FX(+) TAV采用了代的设计改进.
- 这些修改旨在提高程序精度和门部署.
- 优化植入对于急性和长期结果至关重要.
结论:
- Evolut FX(+) TAV平台的设计是为了优化索引植入.
- 代的设计变化提高了TAVI适合不同患者群体的适用性.
- 优化植入影响即时的手术成功和长期的患者利益.
相关概念视频
Mitral Valve Prolapse II: Assessment and Management
389
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
389
Aortic Regurgitation III: Medical Management
379
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
379
Mitral Stenosis III: Medical Management
224
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
224
Mitral Regurgitation III: Medical Management
258
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
258
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Mitral Valve Prolapse III: Nursing Management
267
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
267


